<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920177</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00104340</org_study_id>
    <nct_id>NCT02920177</nct_id>
  </id_info>
  <brief_title>Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement</brief_title>
  <official_title>Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical response of intra-articular platelet
      rich plasma (PRP) versus corticosteroid injection in patients affected by femoroacetabular
      impingement (FAI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine if PRP treatment of FAI improves (i) patient reported outcome
      scores and (ii) hip functional stability compared to standard corticosteroid treatment and if
      PRP treatment of FAI reduces (i) radiographic and (ii) biochemical markers of joint
      inflammation and cartilage degradation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollment
  </why_stopped>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Actual">August 10, 2018</completion_date>
  <primary_completion_date type="Actual">August 10, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Pain Score on the Visual Analog Scale</measure>
    <time_frame>12 months</time_frame>
    <description>VAS score is determined by measuring the distance (mm) on the 10-cm line between the &quot;no pain&quot; anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hip Disability and Osteoarthritis Outcome Score (HOOS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), Calculated as a Sub-score of the HOOS</measure>
    <time_frame>12 months</time_frame>
    <description>Measure Description: Hip Disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
The WOMAC (Western Ontario and McMaster Universities) index is used to assess patients with osteoarthritis of the hip or knee and contains 24 questions, targeting areas of pain, stiffness and physical function. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). WOMAC total is the sum of the three components and it ranges from 0 to 96 points, being 96 the worst outcome.
The questions that are included in the WOMAC are a subgroup of questions that are included in the HOOS, so because of this the HOOS survey can also be used to calculate the WOMAC score for patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measurement Information System (PROMIS) Global Health Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. Global mental health scores range from 0 - 100, and higher scores indicate better mental health.
Global physical health measures overall physical health, physical function, pain and fatigue. Physical global health scores range from 0 - 100, and higher scores indicate better physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Biomarker Analysis: IFN-g, IL-6, MCP-1, MIP-1b, IL-1b, TNF-alpha, Highly Sensitive CRP, COMP.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kellgren-Lawrence Classification Scores</measure>
    <time_frame>12 months</time_frame>
    <description>Calculated from anterior-posterior (AP) pelvis radiographs. Kellgren Lawrence grading system was intended to be utilized analyzing pre-treatment and post-treatment radiographs of the knee. Grading is from 1 to 4 with 1 being minimal to mild disease and 4 being end stage joint disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Femoroacetabular Impingement</condition>
  <arm_group>
    <arm_group_label>platelet-rich plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kenalog 10 mg/mL Injectable Suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>corticosteroid injection into the head-neck junction of the hip joint</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>platelet-rich plasma injection</intervention_name>
    <description>platelet-rich plasma injection</description>
    <arm_group_label>platelet-rich plasma</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenalog 10 MG/ML Injectable Suspension</intervention_name>
    <description>4 mL corticosteroid injection</description>
    <arm_group_label>Kenalog 10 mg/mL Injectable Suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic FAI

          -  Clinical and radiographic evidence of FAI

          -  Patients able to provide consent to study participation

          -  Completion of 6 weeks of physical therapy program

        Exclusion Criteria:

          -  Established Osteoarthritis (Kellgren-Lawrence &gt; 3)

          -  Minimum joint space &gt; 2 mm as measured on AP radiograph

          -  Hip dysplasia (center edge angle &lt; 20Â° on AP radiograph)

          -  Patients with clinically significant cardiovascular, renal, hepatic, endocrine
             disease, cancer or diabetes

          -  Patients with ongoing infection including HIV and Hepatitis

          -  Patient with history of osteomyelitis/septic arthritis

          -  Anticoagulation therapy

          -  Patients who are pregnant or breast feeding

          -  Patients with systemic, rheumatic or inflammatory disease of the knee or
             chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee
             associated with juxta-articular Paget's disease of the femur or tibia, hemophilic
             arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and
             synovial chondromatosis

          -  Patients taking immunosuppressant medication

          -  Patients with abnormal hematology or serum chemistry lab results

          -  Patients receiving injection to treatment knee within 2 months of study enrollment

          -  BMI greater than 35 or less than 20
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tariq M Awan, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <results_first_submitted>March 19, 2020</results_first_submitted>
  <results_first_submitted_qc>March 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2020</results_first_posted>
  <disposition_first_submitted>August 5, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 13, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 19, 2019</disposition_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Tariq Awan</investigator_full_name>
    <investigator_title>Assistant Professor in Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Femoracetabular Impingement</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone Acetonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02920177/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Platelet-rich Plasma</title>
          <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
        </group>
        <group group_id="P2">
          <title>Kenalog 10 mg/mL Injectable Suspension</title>
          <description>corticosteroid injection into the head-neck junction of the hip joint</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Platelet-rich Plasma</title>
          <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
        </group>
        <group group_id="B2">
          <title>Kenalog 10 mg/mL Injectable Suspension</title>
          <description>corticosteroid injection into the head-neck junction of the hip joint</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kellgren-Lawrence classification scores</title>
          <description>Kellgren Lawrence grading system will be utilized analyzing pre-treatment and post-treatment radiographs of the knee. Grading is from 1 to 4 with 1 being minimal to mild disease and 4 being end stage joint disease.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain as measured by Visual Analog Scale (VAS)</title>
          <description>VAS score is determined by measuring the distance (mm) on the 10-cm line between the âno painâ anchor and the patient's mark, providing a range of scores from 0â100. A higher score indicates greater pain intensity.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" lower_limit="50" upper_limit="57"/>
                    <measurement group_id="B2" value="53" lower_limit="40" upper_limit="66"/>
                    <measurement group_id="B3" value="53.25" lower_limit="40" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Biomarkers</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>IFN-g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1b</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1b</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high-sensitivity CRP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COMP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Samples were collected, but never analyzed as the study was terminated before any outcome measure data could be collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOOS Hip Survey</title>
          <description>Hip Disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is scored separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>HOOS Symptom Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="40" upper_limit="75"/>
                    <measurement group_id="B2" value="47.5" lower_limit="45" upper_limit="50"/>
                    <measurement group_id="B3" value="52.5" lower_limit="40" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOOS Activities of Daily Living</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84" lower_limit="72" upper_limit="96"/>
                    <measurement group_id="B2" value="61.5" lower_limit="59" upper_limit="64"/>
                    <measurement group_id="B3" value="72.75" lower_limit="59" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOOS Sports and Recreation Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.5" lower_limit="81" upper_limit="88"/>
                    <measurement group_id="B2" value="45.5" lower_limit="25" upper_limit="66"/>
                    <measurement group_id="B3" value="65" lower_limit="25" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOOS Quality of Life Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" lower_limit="44" upper_limit="63"/>
                    <measurement group_id="B2" value="23" lower_limit="19" upper_limit="27"/>
                    <measurement group_id="B3" value="38.25" lower_limit="19" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOOS Pain Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" lower_limit="60" upper_limit="85"/>
                    <measurement group_id="B2" value="50" lower_limit="45" upper_limit="55"/>
                    <measurement group_id="B3" value="61.25" lower_limit="45" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Reported Outcome Measurement Information System (PROMIS) Global Health Scale</title>
          <description>Global physical health measures overall physical health, physical function, pain and fatigue. Physical global health scores range from 0 - 100, and higher scores indicate better physical health.
Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. Global mental health scores range from 0 - 100, and higher scores indicate better mental health.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Physical Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="15" upper_limit="17"/>
                    <measurement group_id="B2" value="16" lower_limit="16" upper_limit="16"/>
                    <measurement group_id="B3" value="16" lower_limit="15" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="B2" value="13" lower_limit="12" upper_limit="14"/>
                    <measurement group_id="B3" value="13.75" lower_limit="12" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pain Score on the Visual Analog Scale</title>
        <description>VAS score is determined by measuring the distance (mm) on the 10-cm line between the &quot;no pain&quot; anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.</description>
        <time_frame>12 months</time_frame>
        <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Platelet-rich Plasma</title>
            <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
          </group>
          <group group_id="O2">
            <title>Kenalog 10 mg/mL Injectable Suspension</title>
            <description>corticosteroid injection into the head-neck junction of the hip joint</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Score on the Visual Analog Scale</title>
          <description>VAS score is determined by measuring the distance (mm) on the 10-cm line between the &quot;no pain&quot; anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.</description>
          <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hip Disability and Osteoarthritis Outcome Score (HOOS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), Calculated as a Sub-score of the HOOS</title>
        <description>Measure Description: Hip Disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
The WOMAC (Western Ontario and McMaster Universities) index is used to assess patients with osteoarthritis of the hip or knee and contains 24 questions, targeting areas of pain, stiffness and physical function. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). WOMAC total is the sum of the three components and it ranges from 0 to 96 points, being 96 the worst outcome.
The questions that are included in the WOMAC are a subgroup of questions that are included in the HOOS, so because of this the HOOS survey can also be used to calculate the WOMAC score for patients.</description>
        <time_frame>12 months</time_frame>
        <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Platelet-rich Plasma</title>
            <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
          </group>
          <group group_id="O2">
            <title>Kenalog 10 mg/mL Injectable Suspension</title>
            <description>corticosteroid injection into the head-neck junction of the hip joint</description>
          </group>
        </group_list>
        <measure>
          <title>Hip Disability and Osteoarthritis Outcome Score (HOOS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), Calculated as a Sub-score of the HOOS</title>
          <description>Measure Description: Hip Disability and Osteoarthritis Outcome Score (HOOS) is a hip-specific patient-reported outcome measure that has 5 subscales. Each subscale is score separately and ranges from 0-100, 100 = no disability, therefore higher values indicate a better outcome.
The WOMAC (Western Ontario and McMaster Universities) index is used to assess patients with osteoarthritis of the hip or knee and contains 24 questions, targeting areas of pain, stiffness and physical function. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). WOMAC total is the sum of the three components and it ranges from 0 to 96 points, being 96 the worst outcome.
The questions that are included in the WOMAC are a subgroup of questions that are included in the HOOS, so because of this the HOOS survey can also be used to calculate the WOMAC score for patients.</description>
          <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome Measurement Information System (PROMIS) Global Health Scale</title>
        <description>Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. Global mental health scores range from 0 - 100, and higher scores indicate better mental health.
Global physical health measures overall physical health, physical function, pain and fatigue. Physical global health scores range from 0 - 100, and higher scores indicate better physical health.</description>
        <time_frame>12 months</time_frame>
        <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Platelet-rich Plasma</title>
            <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
          </group>
          <group group_id="O2">
            <title>Kenalog 10 mg/mL Injectable Suspension</title>
            <description>corticosteroid injection into the head-neck junction of the hip joint</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcome Measurement Information System (PROMIS) Global Health Scale</title>
          <description>Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. Global mental health scores range from 0 - 100, and higher scores indicate better mental health.
Global physical health measures overall physical health, physical function, pain and fatigue. Physical global health scores range from 0 - 100, and higher scores indicate better physical health.</description>
          <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Biomarker Analysis: IFN-g, IL-6, MCP-1, MIP-1b, IL-1b, TNF-alpha, Highly Sensitive CRP, COMP.</title>
        <time_frame>12 months</time_frame>
        <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Platelet-rich Plasma</title>
            <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
          </group>
          <group group_id="O2">
            <title>Kenalog 10 mg/mL Injectable Suspension</title>
            <description>corticosteroid injection into the head-neck junction of the hip joint</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Biomarker Analysis: IFN-g, IL-6, MCP-1, MIP-1b, IL-1b, TNF-alpha, Highly Sensitive CRP, COMP.</title>
          <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Kellgren-Lawrence Classification Scores</title>
        <description>Calculated from anterior-posterior (AP) pelvis radiographs. Kellgren Lawrence grading system was intended to be utilized analyzing pre-treatment and post-treatment radiographs of the knee. Grading is from 1 to 4 with 1 being minimal to mild disease and 4 being end stage joint disease.</description>
        <time_frame>12 months</time_frame>
        <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Platelet-rich Plasma</title>
            <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
          </group>
          <group group_id="O2">
            <title>Kenalog 10 mg/mL Injectable Suspension</title>
            <description>corticosteroid injection into the head-neck junction of the hip joint</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Kellgren-Lawrence Classification Scores</title>
          <description>Calculated from anterior-posterior (AP) pelvis radiographs. Kellgren Lawrence grading system was intended to be utilized analyzing pre-treatment and post-treatment radiographs of the knee. Grading is from 1 to 4 with 1 being minimal to mild disease and 4 being end stage joint disease.</description>
          <population>No twelve month data was collected because none of the endpoints were reached. All participants left the study before the 6 month follow up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Platelet-rich Plasma</title>
          <description>platelet-rich plasma injection into the head-neck junction of the hip joint</description>
        </group>
        <group group_id="E2">
          <title>Kenalog 10 mg/mL Injectable Suspension</title>
          <description>corticosteroid injection into the head-neck junction of the hip joint</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment was supposed to take place in the first year, but was extended due to low enrollment. The study was terminated early due to an inability to enroll subjects. All participants left the study before outcome measure data could be collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jordyn Sessel</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-615-0934</phone>
      <email>jsessel@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

